2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N13146
    Azukisaponin VI 82801-39-6 98%
    Azukisaponin VI is an oligosaccharide isolated from Vigna angularis. Azukisaponin VI has the activity of inhibiting the synthesis of lipid peroxides and can be used in the study of hyperlipidemia.
    Azukisaponin VI
  • HY-N13380
    6′‐O‐Galloylsalidroside 83013-86-9 98%
    6’-O-Galloylsalidroside is an active component of Rhodiola. 6’-O-Galloylsalidroside is promising for research of Alzheimer’s disease, lung diseases, cerebrovascular disease, diabetes, cardiovascular disease and aging-related diseases.
    6′‐O‐Galloylsalidroside
  • HY-N1353R
    Rhamnocitrin (Standard) 569-92-6
    Rhamnocitrin (Standard) is the analytical standard of Rhamnocitrin. This product is intended for research and analytical applications. Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells).
    Rhamnocitrin (Standard)
  • HY-N1370R
    Tanshinone IIA sulfonate sodium (Standard) 69659-80-9 98%
    Tanshinone IIA sulfonate (sodium) (Standard) is the analytical standard of Tanshinone IIA sulfonate (sodium). This product is intended for research and analytical applications. Tanshinone IIA sulfonate (sodium) is a derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.
    Tanshinone IIA sulfonate sodium (Standard)
  • HY-N13729
    Stephalonine P 2376309-57-6
    Stephalonine P is a hasubanan-type alkaloid anti-inflammatory agent with neuroprotective effects against neuroinflammation. Stephalonine P regulates post-ischemic inflammatory responses by inhibiting NO production in LPS-activated BV2 microglia (IC50=34.01 μM), thereby reducing microglial activation and neuronal damage. Stephalonine P can be isolated from the whole plant of Stephania japonica. Stephalonine P can be used in research on stroke and other neuroinflammation-related diseases.
    Stephalonine P
  • HY-N13747
    Chrysosplenol C 23370-16-3 98%
    Chrysosplenol C is a type of flavonoid compound. Chrysosplenol C selectively activates cardiac myosin ATPase, with its EC50 being 45 µM. Chrysosplenol C enhances the release of intracellular calcium ions by activating protein kinase C (PKC), thereby increasing the contractility of rat ventricular muscle cells. Chrysosplenol C can be used in the research of heart failure.
    Chrysosplenol C
  • HY-N1400R
    (20R)-Ginsenoside Rh1 (Standard) 80952-71-2
    (20R)-Ginsenoside Rh1 (Standard) is the analytical standard of (20R)-Ginsenoside Rh1 (HY-N1400). This product is intended for research and analytical applications. (20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects.
    (20R)-Ginsenoside Rh1 (Standard)
  • HY-N1444R
    Complanatuside (Standard) 116183-66-5
    Complanatuside (Standard) is the analytical standard of Complanatuside. This product is intended for research and analytical applications. Complanatuside is a flavonoid found in the traditional Chinese medicine Semen Astragali Complanati.
    Complanatuside (Standard)
  • HY-N1462R
    Atractyloside potassium salt (Standard) 102130-43-8
    Atractyloside (potassium salt) (Standard) is the analytical standard of Atractyloside (potassium salt). This product is intended for use in research and analytical applications. Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity.
    Atractyloside potassium salt (Standard)
  • HY-N1483A
    Guanfu base A hydrochloride 618094-85-2 98%
    Guanfu base A hydrochloride is an antiarrhythmic alkaloid with the ability to inhibit CYP2D6 enzyme activity. Guanfu base A hydrochloride can be used to inhibit arrhythmia-related diseases. Guanfu base A hydrochloride exhibits inhibitory effects on CYP2D6 in different species of organisms, including humans, monkeys, and dogs. The biological activity of Guanfu base A hydrochloride makes it have potential clinical application value.
    Guanfu base A hydrochloride
  • HY-N15447
    Visnaginone 484-27-5 98%
    Visnaginone is the derivative of Visnagin (HY-N1082). Visnagin, an antioxidant furanocoumarin derivative, possess anti-inflammatory and analgesic properties. Visnagin has substantial potential to prevent Cerulein induced acute pancreatitis (AP). Visnagin possess promising vasodilator effects in vascular smooth muscles.
    Visnaginone
  • HY-N15524
    Thalictoside 74213-96-0 98%
    Thalictoside is found in A. squamosa L. Thalictoside is a sEH inhibitor (IC50: 20.2 µM). Thalictoside exerts anti-osteoporotic effects through an estrogen-like mechanism. Thalictoside can be used in the research of cardiovascular and urinary diseases.
    Thalictoside
  • HY-N15525
    Arabinothalictoside 153287-94-6 98%
    Arabinothalictoside is found in A. squamosa L. Arabinothalictoside is a sEH inhibitor (IC50: 47.1 µM). Arabinothalictoside can be used in the research of cardiovascular and urinary diseases.
    Arabinothalictoside
  • HY-N15536
    N-trans-Feruloyltyramine 4′-O-β-D-glucopyranoside 1251952-80-3 98%
    N-trans-Feruloyltyramine 4′-O-β-D-glucopyranoside is a phenolic amide glycoside compound found in Suaeda japonica. N-trans-Feruloyltyramine 4′-O-β-D-glucopyranoside exhibits antioxidant activity, capable of effectively scavenging DPPH free radicals and reducing the production of ROS induced by H2O2 in cells, thus protecting cells from oxidative stress damage. N-trans-Feruloyltyramine 4′-O-β-D-glucopyranoside is promising for research of cardiovascular diseases and neurodegenerative diseases.
    N-trans-Feruloyltyramine 4′-O-β-D-glucopyranoside
  • HY-N15660
    Azafrin 507-61-9
    Azafrin, a carotenoid, is one of the most abundant active ingredients in C. grandiflora. Azafrin increases HO-1, NQO1, and Nrf2 expression. Azafrin shows cardioprotective effect against myocardial injury via activation of the Nrf2-ARE pathway. Azafrin can be used for research of cardiovascular diseases.
    Azafrin
  • HY-N15700
    Toralactone 9-O-triglucoside 1002727-59-4 98%
    Toralactone 9-O-triglucoside (Compound 2) is a phenolic trisaccharide. Toralactone 9-O-triglucoside can be isolated from Cassia seed. Toralactone 9-O-triglucoside can be used in the research of estrogen-related diseases such as breast cancer, prostate cancer, osteoporosis and cardiovascular disease.
    Toralactone 9-O-triglucoside
  • HY-N15706
    Luteolin-7-O-β-D-glucuronide methyl ester 76939-42-9
    Luteolin-7-O-β-D-glucuronide methyl ester is a flavonoid with antioxidative activity. Luteolin-7-O-β-D-glucuronide methyl ester exhibits potent antioxidative activity with an IC50 of 3.05 μg/mL in the NBT superoxide scavenging assay. Luteolin-7-O-β-D-glucuronide methyl ester inhibits LDL oxidation induced by Cu2+ with the IC50 value is 71.13 μg/mL.
    Luteolin-7-O-β-D-glucuronide methyl ester
  • HY-N15735
    Cimicifugic acid D 219986-51-3
    Cimicifugic acid D (2-Caffeoylpiscidic acid) is a benzyltartaric acid ester that induces vasodilation of precontracted rat aortic strips and endothelium-independent relaxation mechanism. Cimicifugic acid D inhibits extracellular Ca2+ influx through receptor-operated Ca2+ channels (ROC) in Norepinephrine (HY-13715)-induced contraction of rat aortic strips, without affecting voltage-dependent Ca2+ channels (VDC) or K+-induced contractions.
    Cimicifugic acid D
  • HY-N15737
    Fukinolic acid 50982-40-6
    Fukinolic acid is a benzyltartaric acid ester, is a vasodilator with antiviral activity against enterovirus A71 (EV-A71) replication. Fukinolic acid is a receptor-operated Ca2+ channels (ROC) inhibitor, suppressing extracellular Ca2+ influx through ROC activated by Norepinephrine (HY-13715) without affecting voltage-dependent Ca2+ channels.
    Fukinolic acid
  • HY-N15743
    Anti-Heart Failure Agent 2 2901143-46-0
    Anti-Heart Failure Agent 2 (Compound 1) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 2 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 2 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 2 is promising for research of heart failure.
    Anti-Heart Failure Agent 2
Cat. No. Product Name / Synonyms Application Reactivity